ANI Pharmaceuticals Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 897

Employees

  • Stock Symbol
  • ANIP

Stock Symbol

  • Investments
  • 29

  • Share Price
  • $62.12
  • (As of Thursday Closing)

ANI Pharmaceuticals General Information

Description

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Contact Information

Formerly Known As
BioSante Pharmaceuticals, Ben Abraham Technologies Inc
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 210 Main Street West
  • Baudette, MN 56623
  • United States
+1 (218)
Primary Industry
Pharmaceuticals
Other Industries
Other Healthcare Services
Stock Exchange
NAS
Corporate Office
  • 210 Main Street West
  • Baudette, MN 56623
  • United States
+1 (218)

ANI Pharmaceuticals Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ANI Pharmaceuticals Stock Performance

As of 12-Jun-2025, ANI Pharmaceuticals’s stock price is $62.12. Its current market cap is $1.34B with 21.7M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$62.12 $62.78 $52.50 - $77.00 $1.34B 21.7M 396K -$1.26

ANI Pharmaceuticals Financials Summary

As of 31-Mar-2025, ANI Pharmaceuticals has a trailing 12-month revenue of $674M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 1,954,783 1,658,796 1,243,981 957,468
Revenue 674,068 614,376 486,816 316,385
EBITDA 66,862 63,121 106,603 25,040
Net Income (21,048) (18,522) 18,779 (47,896)
Total Assets 1,292,428 1,283,697 904,422 760,087
Total Debt 622,822 624,092 285,669 286,519
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ANI Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ANI Pharmaceuticals‘s full profile, request access.

Request a free trial

ANI Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid
Pharmaceuticals
Baudette, MN
897 As of 2024

Haifa Bay, Israel
 

Trevose, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ANI Pharmaceuticals Competitors (21)

One of ANI Pharmaceuticals’s 21 competitors is Taro Pharmaceutical Industries, a Corporate Backed or Acquired company based in Haifa Bay, Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Taro Pharmaceutical Industries Corporate Backed or Acquired Haifa Bay, Israel
Lannett Company Corporation Trevose, PA
Breckenridge Pharmaceutical Corporate Backed or Acquired NJ
Padagis Private Equity-Backed Allegan, MI
Amneal Pharmaceuticals Formerly PE-Backed Bridgewater, NJ
You’re viewing 5 of 21 competitors. Get the full list »

ANI Pharmaceuticals Patents

ANI Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11975047-B1 Methods for storing and warming purified corticotropin compositions Active 28-Oct-2022
US-12102662-B1 Methods for storing and warming purified corticotropin compositions Active 28-Oct-2022
US-12133831-B1 Kits for preparing and delivering purified corticotropin Active 28-Oct-2022
US-12233105-B1 Methods for storing and warming purified corticotropin compositions Active 28-Oct-2022
US-12324787-B1 Kits for preparing and delivering purified corticotropin Active 28-Oct-2022 A61J1/1443
To view ANI Pharmaceuticals’s complete patent history, request access »

ANI Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ANI Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ANI Pharmaceuticals‘s full profile, request access.

Request a free trial

ANI Pharmaceuticals Investments & Acquisitions (29)

ANI Pharmaceuticals’s most recent deal was a Merger/Acquisition with Alimera Sciences for . The deal was made on 16-Sep-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alimera Sciences 16-Sep-2024 Merger/Acquisition Pharmaceuticals
Alvogen (Certain Pharmaceutical Products Rights in Morristown, New Jersey) 27-Dec-2023 Corporate Asset Purchase Buildings and Property
Slayback Pharma (ANDA, Registered Patents and Patent Applications in Princeton, New Jersey) 14-Aug-2023 Corporate Asset Purchase Buildings and Property
Akorn (ANDA Assets) 15-Jun-2023 Corporate Asset Purchase Buildings and Property
Oakrum Pharma (Portfolio Four Abbreviated New Drug Applications) 21-Jul-2022 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 29 investments and acquisitions. Get the full list »

ANI Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated January, 18, 2025

39 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view ANI Pharmaceuticals’s complete esg history, request access »

ANI Pharmaceuticals Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
ANI Pharmaceuticals Canada Oakville, Canada 2018
Novitium East Windsor, NJ 2016
Alimera Sciences Alpharetta, GA 2003

ANI Pharmaceuticals FAQs

  • When was ANI Pharmaceuticals founded?

    ANI Pharmaceuticals was founded in 1996.

  • Where is ANI Pharmaceuticals headquartered?

    ANI Pharmaceuticals is headquartered in Baudette, MN.

  • What is the size of ANI Pharmaceuticals?

    ANI Pharmaceuticals has 897 total employees.

  • What industry is ANI Pharmaceuticals in?

    ANI Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is ANI Pharmaceuticals a private or public company?

    ANI Pharmaceuticals is a Public company.

  • What is ANI Pharmaceuticals’s stock symbol?

    The ticker symbol for ANI Pharmaceuticals is ANIP.

  • What is the current stock price of ANI Pharmaceuticals?

    As of 12-Jun-2025 the stock price of ANI Pharmaceuticals is $62.12.

  • What is the current market cap of ANI Pharmaceuticals?

    The current market capitalization of ANI Pharmaceuticals is $1.34B.

  • What is ANI Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for ANI Pharmaceuticals is $674M.

  • Who are ANI Pharmaceuticals’s competitors?

    Taro Pharmaceutical Industries, Lannett Company, Breckenridge Pharmaceutical, Padagis, and Amneal Pharmaceuticals are some of the 21 competitors of ANI Pharmaceuticals.

  • What is ANI Pharmaceuticals’s annual earnings per share (EPS)?

    ANI Pharmaceuticals’s EPS for 12 months was -$1.26.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »